Literature DB >> 26041301

Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.

Shihong Zhang1, Rakesh K Bakshi1, Pothakamuri Venkata Suneetha2, Paraskevi Fytili2, Dinler A Antunes3, Gustavo F Vieira3, Roland Jacobs4, Christoph S Klade5, Michael P Manns2, Anke R M Kraft2, Heiner Wedemeyer2, Verena Schlaphoff2, Markus Cornberg6.   

Abstract

UNLABELLED: T cell responses play a critical role in controlling or clearing viruses. Therefore, strategies to prevent or treat infections include boosting T cell responses. T cells specific for various pathogens have been reported in unexposed individuals and an influence of such cells on the response toward vaccines is conceivable. However, little is known about their frequency, repertoire, and impact on vaccination. We performed a detailed characterization of CD8(+) T cells specific to a hepatitis C virus (HCV) epitope (NS3-1073) in 121 HCV-seronegative individuals. We show that in vitro HCV NS3-1073-specific CD8(+) T cell responses were rather abundantly detectable in one-third of HCV-seronegative individuals irrespective of risk factors for HCV exposure. Ex vivo, these NS3-1073-specific CD8(+) T cells were found to be both naive and memory cells. Importantly, recognition of various peptides derived from unrelated viruses by NS3-1073-specific CD8(+) T cells showed a considerable degree of T cell cross-reactivity, suggesting that they might in part originate from previous heterologous infections. Finally, we further provide evidence that preexisting NS3-1073-specific CD8(+) T cells can impact the T cell response toward peptide vaccination. Healthy, vaccinated individuals who showed an in vitro response toward NS3-1073 already before vaccination displayed a more vigorous and earlier response toward the vaccine. IMPORTANCE: Preventive and therapeutic vaccines are being developed for many viral infections and often aim on inducing T cell responses. Despite effective antiviral drugs against HCV, there is still a need for a preventive vaccine. However, the responses to vaccines can be highly variable among different individuals. Preexisting T cells in unexposed individuals could be one reason that helps to explain the variable T cell responses to vaccines. Based on our findings, we suggest that HCV CD8(+) T cells are abundant in HCV-seronegative individuals but that their repertoire is highly diverse due to the involvement of both naive precursors and cross-reactive memory cells of different specificities, which can influence the response to vaccines. The data may emphasize the need to personalize immune-based therapies based on the individual's T cell repertoire that is present before the immune intervention.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26041301      PMCID: PMC4524240          DOI: 10.1128/JVI.00539-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity.

Authors:  Markus Cornberg; Alex T Chen; Lee A Wilkinson; Michael A Brehm; Sung-Kwon Kim; Claudia Calcagno; Dario Ghersi; Roberto Puzone; Franco Celada; Raymond M Welsh; Liisa K Selin
Journal:  J Clin Invest       Date:  2006-04-13       Impact factor: 14.808

Review 2.  Private specificities of heterologous immunity.

Authors:  Raymond M Welsh
Journal:  Curr Opin Immunol       Date:  2006-04-04       Impact factor: 7.486

3.  Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

Authors:  Christa Firbas; Bernd Jilma; Erich Tauber; Vera Buerger; Sandra Jelovcan; Karen Lingnau; Michael Buschle; Jürgen Frisch; Christoph S Klade
Journal:  Vaccine       Date:  2006-03-20       Impact factor: 3.641

4.  Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.

Authors:  P Fytili; G N Dalekos; V Schlaphoff; P V Suneetha; C Sarrazin; W Zauner; K Zachou; T Berg; M P Manns; C S Klade; M Cornberg; H Wedemeyer
Journal:  Vaccine       Date:  2008-06-10       Impact factor: 3.641

5.  Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection.

Authors:  Bérangère Neveu; Emilie Debeaupuis; Klara Echasserieau; Béatrice le Moullac-Vaidye; Michelle Gassin; Loïg Jegou; Jérémie Decalf; Matthew Albert; Nicolas Ferry; Jérôme Gournay; Elisabeth Houssaint; Marc Bonneville; Xavier Saulquin
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

6.  Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus.

Authors:  Victoria Kasprowicz; Scott M Ward; Alison Turner; Alexandros Grammatikos; Brian E Nolan; Lia Lewis-Ximenez; Charles Sharp; Jenny Woodruff; Vicki M Fleming; Stuart Sims; Bruce D Walker; Andrew K Sewell; Georg M Lauer; Paul Klenerman
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

Review 7.  Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity.

Authors:  Liisa K Selin; Michael A Brehm; Yuri N Naumov; Markus Cornberg; Sung-Kwon Kim; Shalyn C Clute; Raymond M Welsh
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

8.  Heterologous T cell immunity in severe hepatitis C virus infection.

Authors:  Simona Urbani; Barbara Amadei; Paola Fisicaro; Massimo Pilli; Gabriele Missale; Antonio Bertoletti; Carlo Ferrari
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

9.  Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response.

Authors:  Manuela F Meyer; Marc Lehmann; Markus Cornberg; Johannes Wiegand; Michael P Manns; Christoph Klade; Heiner Wedemeyer
Journal:  Virol J       Date:  2007-06-11       Impact factor: 4.099

Review 10.  Pathogenic epitopes, heterologous immunity and vaccine design.

Authors:  Raymond M Welsh; Robert S Fujinami
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

View more
  20 in total

1.  Distinct peripheral vs mucosal T-cell phenotypes in chlamydia-infected women.

Authors:  Brian M O Ogendi; Rakesh K Bakshi; Steffanie Sabbaj; LaDraka' Brown; Jeannette Y Lee; Richa Kapil; William M Geisler
Journal:  Am J Reprod Immunol       Date:  2017-09-26       Impact factor: 3.886

2.  T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions.

Authors:  Brian M O Ogendi; Rakesh K Bakshi; Kanupriya Gupta; Richa Kapil; LaDraka T Brown; Stephen J Jordan; Steffanie Sabbaj; Christen G Press; Jeannette Y Lee; William M Geisler
Journal:  Microbes Infect       Date:  2017-12-26       Impact factor: 2.700

3.  The Predominant CD4+ Th1 Cytokine Elicited to Chlamydia trachomatis Infection in Women Is Tumor Necrosis Factor Alpha and Not Interferon Gamma.

Authors:  Stephen J Jordan; Kanupriya Gupta; Brian M O Ogendi; Rakesh K Bakshi; Richa Kapil; Christen G Press; Steffanie Sabbaj; Jeannette Y Lee; William M Geisler
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

Review 4.  Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension.

Authors:  Babita Agrawal; Shakti Singh; Nancy Gupta; Wen Li; Satish Vedi; Rakesh Kumar
Journal:  Int J Mol Sci       Date:  2017-07-27       Impact factor: 5.923

5.  Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.

Authors:  Dinler A Antunes; Maurício M Rigo; Martiela V Freitas; Marcus F A Mendes; Marialva Sinigaglia; Gregory Lizée; Lydia E Kavraki; Liisa K Selin; Markus Cornberg; Gustavo F Vieira
Journal:  Front Immunol       Date:  2017-10-04       Impact factor: 7.561

6.  Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires.

Authors:  Nuray Aslan; Levi B Watkin; Anna Gil; Rabinarayan Mishra; Fransenio G Clark; Raymond M Welsh; Dario Ghersi; Katherine Luzuriaga; Liisa K Selin
Journal:  mBio       Date:  2017-12-05       Impact factor: 7.867

7.  Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance.

Authors:  Mohamed S Abdel-Hakeem; Maude Boisvert; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  PLoS Pathog       Date:  2017-02-01       Impact factor: 6.823

8.  General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept.

Authors:  Dinler A Antunes; Didier Devaurs; Mark Moll; Gregory Lizée; Lydia E Kavraki
Journal:  Sci Rep       Date:  2018-03-12       Impact factor: 4.379

9.  Expansion of Unique Hepatitis C Virus-Specific Public CD8+ T Cell Clonotypes during Acute Infection and Reinfection.

Authors:  Sabrina Mazouz; Maude Boisvert; Mohamed S Abdel-Hakeem; Omar Khedr; Julie Bruneau; Naglaa H Shoukry
Journal:  J Immunol       Date:  2021-08-02       Impact factor: 5.426

10.  DockTope: a Web-based tool for automated pMHC-I modelling.

Authors:  Maurício Menegatti Rigo; Dinler Amaral Antunes; Martiela Vaz de Freitas; Marcus Fabiano de Almeida Mendes; Lindolfo Meira; Marialva Sinigaglia; Gustavo Fioravanti Vieira
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.